Biopharmaceutical manufacturing faces many new opportunities as we enter this decade. ISPE is returning to Boston for the 2020 ISPE Biopharmaceutical Manufacturing Conference on 1-3 June 2020, bringing you once again an innovative conference, followed by the 2020 ISPE Continuous Manufacturing Workshop and relevant training classes 4-5 June 2020. The Boston area, including Cambridge, is home to over 1,000 biotechnology companies, leading research, and academic institutions advancing biotechnology medicines.
This year, the 2020 ISPE Biopharmaceutical Manufacturing Conference will focus on advances in manufacturing, facilities, and analytics important to bring new therapies to patients. Now more than ever, manufacturing is on the critical path as many new treatments in the area of personalized medicines and individualized batch production present the challenge to bring these medicines through rapid development, reliable manufacturing, and availability to patients a pace with the advances clinical research is bringing to address unmet needs. At the same time, biosimilars are advancing with the opportunity to provide more access to medicines.
Topics that will be addressed at this conference include:
Session leaders and speakers are top leaders and experts in their fields of industry, regulatory, and/or academia. Topics will cover how we continually improve and manufacture our current processes, and continue to advance into new modalities. At the same time, the sessions will address how conventional norms of manufacturing testing and regulatory GMP and CMC oversight are advancing to meet patient needs.
Keep watching as our agenda advances, with updates from our planning committee. I look forward to seeing you in Boston in June.
The future of the pharmaceutical industry is being shaped by rapid advancements in digital technologies, automation, and data analytics. As we look ahead to 2025, the concept of Pharma 4.0™ is no longer just an aspirational vision—it is becoming a transformative reality that will redefine how medicines are developed, manufactured, and delivered to patients.
Lindsey Daniel, Director of Product Operations Strategy and Business Lead at Takeda, is an exemplary champion for and beneficiary of ISPE. Daniel embodies leadership and collaboration in numerous ways: as a mentor, mentee, friend, colleague, mother, and more. With over 12 years of active involvement with ISPE, she has served on various committees, including ISPE’s International Women in...
In the pharmaceutical industry, ensuring the safety, quality, and efficacy of products is paramount. With the increasing complexity of manufacturing processes, the growing reliance on computerized systems and advancements in technology, GAMP® guidance provides a framework for validating and maintaining the integrity of computerized systems, ensuring they are fit for their intended...